First-line treatment of ovarian cancer where combination treatment with paclitaxel plus carboplatin is considered to be unsuitable (e.g. because of hypersensitivity to paclitaxel or a strong desire to avoid hair loss). Also used for relapsed ovarian cancer in patients who have had a prolonged (usually > 6 months) disease-free interval after previous platinum treatment.